SUNPHARMA

$SUNPHARMA Sun Pharma is India’s largest pharmaceutical company with a strong presence across specialty medicines, generics and emerging markets. Its differentiated specialty portfolio and global scale support attractive margins and cash generation. FY26 consolidated revenue was approximately ₹56,500 crore, while PAT was around ₹13,700 crore, reflecting strong underlying profitability. Latest News: Sun Pharma recently received approval to manufacture and market generic semaglutide in South Africa, strengthening its GLP-1 opportunity. Q1 FY27 results reported operating profit of about ₹2,554 crore and PAT of ₹2,279 crore. Corporate Action: The company continues investing in specialty products, R&D and manufacturing capacity. Strong specialty growth, global expansion and a diversified portfolio provide long-term earnings visibility, while regulatory risks, US pricing pressure and R&D outcomes remain key risks.